ITMI20022511A1 - USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN THE ORDER OF ATRIAL FIBRILLATION. - Google Patents

USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN THE ORDER OF ATRIAL FIBRILLATION.

Info

Publication number
ITMI20022511A1
ITMI20022511A1 IT002511A ITMI20022511A ITMI20022511A1 IT MI20022511 A1 ITMI20022511 A1 IT MI20022511A1 IT 002511 A IT002511 A IT 002511A IT MI20022511 A ITMI20022511 A IT MI20022511A IT MI20022511 A1 ITMI20022511 A1 IT MI20022511A1
Authority
IT
Italy
Prior art keywords
omega
pharmaceutical compositions
order
compositions containing
atrial fibrillation
Prior art date
Application number
IT002511A
Other languages
Italian (it)
Inventor
Jadranka Rogan
Original Assignee
Victorix Assets Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Victorix Assets Ltd filed Critical Victorix Assets Ltd
Priority to IT002511A priority Critical patent/ITMI20022511A1/en
Priority to AU2003292080A priority patent/AU2003292080A1/en
Priority to PCT/EP2003/013125 priority patent/WO2004047835A1/en
Priority to EP03767610A priority patent/EP1565177A1/en
Publication of ITMI20022511A1 publication Critical patent/ITMI20022511A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IT002511A 2002-11-26 2002-11-26 USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN THE ORDER OF ATRIAL FIBRILLATION. ITMI20022511A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IT002511A ITMI20022511A1 (en) 2002-11-26 2002-11-26 USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN THE ORDER OF ATRIAL FIBRILLATION.
AU2003292080A AU2003292080A1 (en) 2002-11-26 2003-11-21 Use of pharmaceutical compositions containing ethyl esters of omega-3 polyunsaturated acids to prevent atrial fibrillation
PCT/EP2003/013125 WO2004047835A1 (en) 2002-11-26 2003-11-21 Use of pharmaceutical compositions containing ethyl esters of omega-3 polyunsaturated acids to prevent atrial fibrillation
EP03767610A EP1565177A1 (en) 2002-11-26 2003-11-21 Use of pharmaceutical compositions containing ethyl esters of omega-3 polyunsaturated acids to prevent atrial fibrillation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002511A ITMI20022511A1 (en) 2002-11-26 2002-11-26 USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN THE ORDER OF ATRIAL FIBRILLATION.

Publications (1)

Publication Number Publication Date
ITMI20022511A1 true ITMI20022511A1 (en) 2004-05-27

Family

ID=32375543

Family Applications (1)

Application Number Title Priority Date Filing Date
IT002511A ITMI20022511A1 (en) 2002-11-26 2002-11-26 USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN THE ORDER OF ATRIAL FIBRILLATION.

Country Status (4)

Country Link
EP (1) EP1565177A1 (en)
AU (1) AU2003292080A1 (en)
IT (1) ITMI20022511A1 (en)
WO (1) WO2004047835A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
FR2902659A1 (en) * 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa DHA ESTER AND ITS USE IN THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES
WO2008066745A1 (en) * 2006-11-22 2008-06-05 Reliant Pharmaceuticals, Inc. Prophlyaxis and treatment of atrial fibrillation with omega-3 fatty acids
RU2362553C1 (en) * 2007-12-10 2009-07-27 Федеральное государственное учреждение "Федеральный центр сердца, крови и эндокринологии имени В.А. Алмазова Федерального агентства по высокотехнологичной медицинской помощи" Way of prevention of auricles fibrillation after operation of coronary shunting at patients with ischemic heart disease
CN104146955A (en) 2009-03-09 2014-11-19 普罗诺瓦生物医药挪威公司 Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form and a surfactant, and methods and uses thereof
EP4008327A1 (en) * 2009-04-29 2022-06-08 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CA2759284C (en) * 2009-04-29 2016-06-21 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
CN108096209A (en) 2009-06-15 2018-06-01 阿马里纳制药公司 Triglycerides, composition and method without increasing LDL-C levels are reduced in the object of associated Statins therapy
US20110082205A1 (en) * 2009-10-01 2011-04-07 Panker Cynthia A Docosahexaenoic Acid Gel Caps
FR2963790B1 (en) 2010-08-11 2012-09-28 Pf Medicament PANTHENYL DOCOSAHEXAENEOATE AND USE THEREOF IN THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES
SMT202400320T1 (en) 2018-09-24 2024-09-16 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of cardiovascular events in a subject
CN116350616A (en) 2019-11-12 2023-06-30 阿马里纳药物爱尔兰有限公司 Method for reducing the risk of cardiovascular events in subjects with atrial fibrillation and/or atrial flutter
WO2022225896A1 (en) 2021-04-21 2022-10-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1308613B1 (en) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa ESSENTIAL FATTY ACIDS IN THE PREVENTION OF CARDIOVASCULAR EVENTS.
DE60022987T2 (en) * 2000-05-22 2006-10-19 Pro Aparts - Investimentos E Consultoria Lda., Funchal Fatty acid composition containing at least 80% by weight of EPA and DHA
ITMI20010129A1 (en) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa ESSENTIAL FATTY ACIDS IN THE THERAPY OF HEART INSUFFICIENCY AND HEART FAILURE
ITMI20020269A1 (en) * 2002-02-12 2003-08-12 Victorix Assets Ltd USE OF OMEGA-3 POLYUNSATURATED ACID ETHYL STERES IN PATIENTS WITH HEART INSUFFICIENCY

Also Published As

Publication number Publication date
AU2003292080A1 (en) 2004-06-18
WO2004047835A1 (en) 2004-06-10
EP1565177A1 (en) 2005-08-24

Similar Documents

Publication Publication Date Title
ITMI20020269A1 (en) USE OF OMEGA-3 POLYUNSATURATED ACID ETHYL STERES IN PATIENTS WITH HEART INSUFFICIENCY
ITMI20022511A1 (en) USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN THE ORDER OF ATRIAL FIBRILLATION.
GB2409644B (en) Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof
HUP0303817A3 (en) Medium-chain length fatty acids, glycerides and analogues as neutrophile survival and activation factors and pharmaceutical compositions containing them
AU2003202259A1 (en) Lipid compositions, production thereof and of esters
ITMI20020731A1 (en) PHARMACEUTICAL COMPOSITIONS FOR ACETYLSALICYLIC ACID AND OMEGA-3 OILS
AU2003208920A1 (en) Fatty acid-containing compositions and methods for the treatment of cytokine mediated disorders
EE200300297A (en) Use of essential fatty acid containing a mixture of eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester
JP2004115513A5 (en)
EE200200666A (en) Process for the preparation of cyclopropylcarboxylic acid esters and derivatives
ITMI20022627A1 (en) USE OF A MIXTURE OF FATTY ACID ESTERS AS A FUEL
AU2003223930A1 (en) Pharmaceutical use of boronic acids and esters thereof
AU2003217759A8 (en) Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression
BRPI0606445A2 (en) mucin hypersecretion inhibitors and methods of use
AU2003304576A1 (en) Cis-hydrogenated fatty acid coating of medical devices
AU2614200A (en) Composition for stabilizing and potentiating the action of anti-angiogenic substances by polyunsaturated fatty acids
AU2003222083A1 (en) Acid and ester compounds and methods of using the same
ITMI991753A0 (en) PROCESS FOR THE PREPARATION OF NITROXYALKYL ESTERS OF NAPROXEN
ZA200502613B (en) Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
ATE439362T1 (en) ESTERS IN POSITION 20 OF CAMPTOTHECINES
SI1475379T1 (en) Use of skopin ester derivatives for the preparation of medicines
AU2003280387A1 (en) Pharmaceutical formulation comprising azithrocycin monohydrate
IT1292126B1 (en) WAX ESTERS ENRICHED IN UNSATURATED OMEGA-3 FATTY ACIDS, THEIR PREPARATION AND USE
HUP0402490A2 (en) Antiviral and immunestimulant pharmaceutical composition containing polyunsaturated fatty acid esters
ITMI20020115A1 (en) USE OF OMEGA-3 POLYUNSATURATED ACID ETHYL ESTERS IN CARDIAC SUFFICIENCY OPTIENTS